PPARβ/δ selectively induces differentiation and inhibits cell proliferation

Cell Death and Differentiation

Volumn 13, Issue 1, 2006, Pages 53-60

  Kim, D J ^a,b   Bility, M T ^a   Billin, A N ^c   Willson, T M ^c   Gonzalez, F J ^d   Peters, J M ^a,b  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

^b PENNSYLVANIA STATE UNIVERSITY   (United States)

^c GLAXOSMITHKLINE   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Anti inflammatory; Cell proliferation; Differentiation; Ligand activation; Null mouse; Peroxisome proliferator activated receptor

Indexed keywords

ADIPOPHILIN; ANTIINFLAMMATORY AGENT; CELL MARKER; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; GW 0742; INVOLUCRIN; KERATIN; KERATIN 6; LIGAND; LORICRIN; MESSENGER RNA; MYELOPEROXIDASE INHIBITOR; OXIDOREDUCTASE INHIBITOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIRINIXIC ACID; SMALL PROLINE RICH PROTEIN 1A; SMALL PROLINE RICH PROTEIN 2H; TRANSFERASE; TRANSGLUTAMINASE 1; TROGLITAZONE; UNCLASSIFIED DRUG; CALCIUM; ENZYME INHIBITOR; GW0742; PEROXIDASE; PHORBOL 13 ACETATE 12 MYRISTATE; THIAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; DRUG TARGETING; ENZYME INHIBITION; KERATINOCYTE; MITOSIS INHIBITION; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PSORIASIS; SKIN CANCER; SKIN CARCINOGENESIS; SKIN DISEASE; ANIMAL; BIOLOGICAL MODEL; CALCIUM SIGNALING; CELL CULTURE; CELL PROLIFERATION; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; IN VITRO STUDY; METABOLISM; MOUSE MUTANT;

ANIMALIA;

ANIMALS; CALCIUM; CALCIUM SIGNALING; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; ENZYME INHIBITORS; KERATINOCYTES; LIGANDS; MICE; MICE, KNOCKOUT; MODELS, BIOLOGICAL; PEROXIDASE; PPAR-BETA; TETRADECANOYLPHORBOL ACETATE; THIAZOLES;

EID: 33645004402     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/sj.cdd.4401713     Document Type: Article

References (31)

1. Tan NS, Michalik L, Noy N, Yasmin R, Pacot C, Heim M, Fluhmann B, Desvergne B and Wahll W (2001) Critical roles of PPARbeta/delta in keratinocyte response to inflammation. Genes Dev. 15: 3263-3277
2. Schmuth M, Haqq CM, Cairns WJ, Holder JC, Dorsam S, Chang S, Lau P, Fowler AJ, Chuang G, Moser AH, Brown BE, Mao-Qiang M, Uchida Y, Schoonjans K, Auwerx J, Chambon P, Willson TM, Elias PM and Feingold KR (2004) Peroxisome proliferator-activated receptor (PPAR)-beta/delta stimulates differentiation and lipid accumulation in keratinocytes. J. Invest. Dermatol. 122: 971-983
3. Westergaard M, Henningsen J, Svendsen ML, Johansen C, Jensen UB, Schroder HD, Kratchmarova I, Berge RK, Iversen L, Bolund L, Kragballe K and Kristiansen K (2001) Modulation of keratinocyte gene expression and differentiation by PPAR-selective ligands and tetradecylthioacetic acid. J. Invest. Dermatol. 116: 702-712
4. Di-Poi N, Tan NS, Michalik L, Wahli W and Desvergne B (2002) Antiapoptotic role of PPARβ in keratinocytes via transcriptional control of the Akt1 signaling pathway. Mol. Cell. 10: 721-733
5. Peters JM, Lee SS, Li W, Ward JM, Gavrilova O, Everett C, Reitman ML, Hudson LD and Gonzalez FJ (2000) Growth, adipose, brain and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor β(δ). Mol. Cell. Biol. 20: 5119-5128
6. Michalik L, Desvergne B, Tan NS, Basu-Modak S, Escher P, Rieusset J, Peters JM, Kaya G, Gonzalez FJ, Zakany J, Metzger D, Chambon P, Duboule D and Wahli W (2001) Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR)alpha and PPARbeta mutant mice. J. Cell. Biol. 154: 799-814
7. Cheng L, Ding G, Qin Q, Huang Y, Lewis W, He N, Evans RM, Schneider MD, Brako FA, Xiao Y, Chen YE and Yang Q (2004) Cardiomyocyte-restricted peroxisome proliferator-activated receptor-delta deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy. Nat. Med. 10: 1245-1250
8. Wang YX, Lee CH, Tiep S, Yu RT, Ham J, Kang H and Evans RM (2003) Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity. Cell 113: 159-170
9. Kim DJ, Akiyama TE, Harman FS, Burns AM, Shan W, Ward JM, Kennett MJ, Gonzalez FJ and Peters JM (2004) Peroxisome proliferator-activated receptor beta (delta)-dependent regulation of ubiquitin C expression contributes to attenuation of skin carcinogenesis. J. Biol. Chem. 279: 23719-23727
10. Harman FS, Nicol CJ, Marin HE, Ward JM, Gonzalez FJ and Peters JM (2004) Peroxisome proliferator-activated receptor-delta attenuates colon carcinogenesis. Nat. Med. 10: 481-483
11. Matsuura H, Adachi H, Smart RC, Xu X, Arata J and Jetten AM (1999) Correlation between expression of peroxisome proliferator-activated receptor beta and squamous differentiation in epidermal and tracheobronchial epithelial cells. Mol. Cell. Endocrinol. 147: 85-92
12. Dlugosz AA and Yuspa SH (1994) Protein kinase C regulates keratinocyte transglutaminase (TGK) gene expression in cultured primary mouse epidermal keratinocytes induced to terminally differentiate by calcium. J. Invest. Dermatol. 102: 409-414
13. Jetten AM and Harvat BL (1997) Epidermal differentiation and squamous metaplasia: From stem cell to cell death. J. Dermatol. 24: 711-725
14. Hennings H, Michael D, Cheng C, Steinert P, Holbrook K and Yuspa SH (1980) Calcium regulation of growth and differentiation of mouse epidermal cells in culture. Cell 19: 245-254
15. Bloch A (1989) Growth and differentiation signals as determinants of cancer cell proliferation. Adv. Enzyme Regul. 28: 359-374
16. Wei H and Frenkel K (1992) Suppression of tumor promoter-induced oxidative events and DNA damage in vivo by sarcophytol A: A possible mechanism of antipromotion. Cancer Res. 52: 2298-2303
17. Sznaidman ML, Haffner CD, Maloney PR, Fivush A, Chao E, Goreham D, Sierra ML, LeGrumelec C, Xu HE, Montana VG, Lambert MH, Willson TM, Oliver Jr WR and Stembach DD (2003) Novel selective small molecule agonists for peroxisome proliferator-activated receptor delta (PPARdelta)-synthesis and biological activity. Bioorg. Med. Chem. Lett. 13: 1517-1521
18. Chawla A, Lee CH, Barak Y, He W, Rosenfeld J, Liao D, Han J, Kang H and Evans RM (2003) PPAR{delta} is a very low-density lipoprotein sensor in macrophages. Proc. Natl. Acad. Sci. USA 100: 1268-1273
19. Hanley K, Jiang Y, He SS, Friedman M, Elias PM, Bikle DD, Williams ML and Feingold KR (1998) Keratinocyte differentiation is stimulated by activators of the nuclear hormone receptor PPARalpha. J. Invest. Dermatol. 110: 368-375
20. Mao-Qiang M, Fowler AJ, Schmuth M, Lau P, Chang S, Brown BE, Moser AH, Michalik L, Desvergne B, Wahli W, Li M, Metzger D, Chambon PH, Elias PM and Feingold KR (2004) Peroxisome-Proliferator-Activated Receptor (PPAR)-gamma Activation Stimulates Keratinocyte Differentiation. J. Invest. Dermatol. 123: 305-312
21. Komuves LG, Hanley K, Lefebvre AM, Man MQ, Ng DC, Bikle DD, Williams ML, Elias PM, Auwerx J and Feingold KR (2000) Stimulation of PPARalpha promotes epidermal keratinocyte differentiation in vivo. J. Invest. Dermatol. 115: 353-360
22. Tyner AL and Fuchs E (1986) Evidence for posttranscriptional regulation of the keratins expressed during hyperproliferation and malignant transformation in human epidermis. J. Cell Biol. 103: 1945-1955
23. Roop DR, Huitfeldt H, Kilkenny A and Yuspa SH (1987) Regulated expression of differentiation-associated keratins in cultured epidermal cells detected by monospecific antibodies to unique peptides of mouse epidermal keratins. Differentiation 35: 143-150
24. Dlugosz AA, Glick AB, Tennenbaum T, Weinberg WC and Yuspa SH (1995) Isolation and utilization of epidermal keratinocytes for oncogene research. Methods Enzymol. 254: 3-20
25. Michalik L, Desvergne B and Wahli W (2004) Peroxisome-proliferator-activated receptors and cancers: Complex stories. Nat. Rev. Cancer 4: 61-70
26. Burstein HJ, Demetri GD, Mueller E, Sarraf P, Spiegelman BM and Winer EP (2003) Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: A phase II study. Breast Cancer Res. Treat. 79: 391-397
27. Kulke MH, Demetri GD, Sharpless NE, Ryan DP, Shivdasani R, Clark JS, Spiengelman BM, Kim H, Mayer RJ and Fuchs CS (2002) A phase II study of troglitazone, an activator of the PPARgamma receptor, in patients with chemotherapy-resistant metastatic colorectal cancer. Cancer J. 8: 395-399
28. Matsusue K, Peters JM and Gonzalez FJ (2004) PPARβ/δ potentiates PPARγ-stimulated adipocyte differentiation. FASEB J. 18: 1477-1479
29. Hough-Monroe L and Milstone LM (1991) Quantitation of cross-linked protein: An alternative to counting cornified envelopes as an index of keratinocyte differentiation. Anal. Biochem. 199: 25-28
30. Bility MT, Thompson JT, McKee RH, David RM, Butala JH, Vanden Heuvel JP and Peters JM (2004) Activation of mouse and human peroxisome proliferator-activated receptors (PPARs) by phthalate monoesters. Toxicol. Sci. 82: 170-182
31. Kim DJ, Murray IA, Burns AM, Gonzalez FJ, Perdew GH and Peters JM (2005) Peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) inhibits epidermal cell proliferation by down-regulation of kinase activity. J. Biol. Chem. 280: 9519-9527